PRECONGRESS SYMPOSIUM

MOLECULAR DIAGNOSTICS AND TARGETED THERAPY in NSCLC

Festivalna dvorana, Bled, Slovenia
Wednesday, May 14, 2014

Chairpersons: Tanja Čufer (Slovenia), Izidor Kern (Slovenia)

10.00-10.30 Update in targeted therapy of NSCLC
Tanja Čufer (Slovenia)

10.30-11.00 Molecular testing of resistance mechanisms in NSCLC
Helmut Popper (Austria)

11.00-11.30 Sponsored symposium Boehringer Ingelheim
Improving management of advanced NSCLC
2nd generation irreversible ErbB family blocker LUXlun3 and LUXlun6 clinical studies:
efficacy and patient quality of life considerations
Tanja Čufer (Slovenia)

Triple angiokinase inhibitor therapy for advanced NSCLC in the second-line setting
Marko Jakopović (Croatia)

11.30-12.00 Coffee Break

12.30-12.30 Targeted therapy in Central Europe
Robert Pirker (Austria)

12.30-13.00 External quality assurance in molecular testing of NSCLC
Ulrike Gruber Mösenbacher (Austria)

13.00-13.15 Sponsored symposium Astra Zeneca
Clinical value of immunohistochemistry as an alternative method of EGFR mutation detection
Nina Turnšek Hitij (Slovenia)

13.15-14.30 Lunch

Chairpersons: Robert Pirker (Austria), Ales Ryska (Czech Republic)

14.30-15.00 ALK testing algorithms and Czech registry of NSCLC
Ales Ryska (Czech Republic)

15.00-15.30 Sponsored symposium Bioview – Abbott
Vysis FISH automation – expanding your laboratory focus
Dennis Merkle, Elad Kfir

15.30-16.00 Promising targeted drugs for NSCLC
Peter Beržinec (Slovakia)

16.00-16.30 Coffee break
16.30-17.00 Case presentations
Luka Brčić, Marko Jakopović (Croatia)
Istvan Petak (Hungary)

17.00-17.10 Lung cancer morphologic diagnostic guidelines – Czech experience
Ales Ryska (Czech Republic)

17.10-17.30 Sponsored symposium Eli Lilly
The role of histology in the treatment of advanced NSCLC
Katja Mohorčič (Slovenia)